ATE513850T1 - Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten - Google Patents
Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kaltenInfo
- Publication number
- ATE513850T1 ATE513850T1 AT06759514T AT06759514T ATE513850T1 AT E513850 T1 ATE513850 T1 AT E513850T1 AT 06759514 T AT06759514 T AT 06759514T AT 06759514 T AT06759514 T AT 06759514T AT E513850 T1 ATE513850 T1 AT E513850T1
- Authority
- AT
- Austria
- Prior art keywords
- trail
- crystalization
- ligand
- cold
- purifying apo
- Prior art date
Links
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 title 2
- 108700012411 TNFSF10 Proteins 0.000 title 2
- 238000002425 crystallisation Methods 0.000 abstract 1
- 230000008025 crystallization Effects 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/136,842 US7741285B2 (en) | 2001-11-13 | 2005-05-24 | APO-2 ligand/trail formulations |
| PCT/US2006/018137 WO2006127284A2 (en) | 2005-05-24 | 2006-05-10 | Method of purifying apo-2 ligand/trail using crystallisation in the cold |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE513850T1 true ATE513850T1 (de) | 2011-07-15 |
Family
ID=37150024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06759514T ATE513850T1 (de) | 2005-05-24 | 2006-05-10 | Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7741285B2 (de) |
| EP (1) | EP1888624B1 (de) |
| JP (2) | JP2008542269A (de) |
| KR (1) | KR101283802B1 (de) |
| CN (1) | CN101228183B (de) |
| AT (1) | ATE513850T1 (de) |
| AU (1) | AU2006249494B2 (de) |
| BR (1) | BRPI0611368A2 (de) |
| CA (1) | CA2609188C (de) |
| ES (1) | ES2368445T3 (de) |
| IL (1) | IL187396A (de) |
| MX (1) | MX2007014728A (de) |
| NZ (1) | NZ563518A (de) |
| RU (1) | RU2435781C2 (de) |
| WO (1) | WO2006127284A2 (de) |
| ZA (1) | ZA200710325B (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1450847T3 (da) * | 2001-11-13 | 2010-12-13 | Genentech Inc | Apo2-ligand/TRAIL-formuleringer og anvendelser deraf |
| SG181496A1 (en) | 2009-12-18 | 2012-07-30 | Csl Ltd | Method of purifying polypeptides |
| MA41434B1 (fr) * | 2015-01-30 | 2021-03-31 | Oncoceutics Inc | 7-benzyl-4-(4-(trifluorométhyl)benzyl)-1,2,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(4h)-one, ses sels et leur utilisation en thérapie |
| JP6699085B2 (ja) * | 2015-03-25 | 2020-05-27 | 東ソー株式会社 | Ｆｃ結合性タンパク質の精製方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1132471A3 (de) | 1989-09-12 | 2001-11-28 | F. Hoffmann-La Roche Ag | TNF-bindende Proteine |
| ES2253753T3 (es) | 1995-06-29 | 2006-06-01 | Immunex Corporation | Citocina que induce apoptosis. |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| US6030945A (en) | 1996-01-09 | 2000-02-29 | Genentech, Inc. | Apo-2 ligand |
| TWI240627B (en) * | 1996-04-26 | 2005-10-01 | Chugai Pharmaceutical Co Ltd | Erythropoietin solution preparation |
| PT939804E (pt) | 1996-10-25 | 2005-11-30 | Human Genome Sciences Inc | Neutroquina alfa |
| AU713471C (en) | 1996-12-23 | 2002-04-18 | Immunex Corporation | Ligand for receptor activator of NF-kappa B, ligand is member of TNF superfamily |
| DK1012274T4 (da) | 1997-01-28 | 2011-07-25 | Human Genome Sciences Inc | Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L) |
| US6072047A (en) | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
| US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
| US7803615B1 (en) | 1997-03-17 | 2010-09-28 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| HU230547B1 (hu) | 1997-04-16 | 2016-11-28 | Amgen Inc. | Osteoprotegerin-kötő fehérjék és receptorok |
| CA2287085A1 (en) | 1997-04-16 | 1998-10-22 | Millennium Pharmaceuticals, Inc. | Tumor necrosis factor receptor related proteins tango-63d and tango-63e |
| ATE516354T1 (de) | 1997-05-15 | 2011-07-15 | Genentech Inc | Apo-2-rezeptor |
| AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
| CA2301202A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
| AU9376498A (en) | 1997-09-05 | 1999-03-22 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
| US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
| ES2316182T3 (es) | 1998-01-15 | 2009-04-01 | Genentech, Inc. | Ligando apo-2. |
| ES2308836T3 (es) | 1998-03-27 | 2008-12-01 | Genentech, Inc. | Sinergia de los anticuerpos anti-her-2 y de los ligands para l'apo-2. |
| CA2375149A1 (en) | 1999-06-09 | 2000-12-14 | Genentech, Inc. | Apo-2l receptor agonist and cpt-11 synergism |
| JP5118796B2 (ja) | 1999-06-28 | 2013-01-16 | ジェネンテック， インコーポレイテッド | 二価の金属イオンを利用したＡｐｏ−２リガンドの製造方法 |
| EP1303293B1 (de) | 2000-07-27 | 2008-12-03 | Genentech, Inc. | Sequentielle verabreichung von cpt-11 und apo-2l polypeptid |
| DK1450847T3 (da) * | 2001-11-13 | 2010-12-13 | Genentech Inc | Apo2-ligand/TRAIL-formuleringer og anvendelser deraf |
| AU2003297579A1 (en) * | 2002-11-27 | 2004-06-23 | Irm Llc | Methods and compositions for inducing apoptosis in cancer cells |
| CN1473843A (zh) * | 2003-07-24 | 2004-02-11 | 华东理工大学 | 重组 trail 包含体蛋白的工业化提取、复性和纯化方法 |
-
2005
- 2005-05-24 US US11/136,842 patent/US7741285B2/en not_active Expired - Lifetime
-
2006
- 2006-05-10 ES ES06759514T patent/ES2368445T3/es active Active
- 2006-05-10 WO PCT/US2006/018137 patent/WO2006127284A2/en not_active Ceased
- 2006-05-10 NZ NZ563518A patent/NZ563518A/en not_active IP Right Cessation
- 2006-05-10 CN CN2006800271223A patent/CN101228183B/zh not_active Expired - Fee Related
- 2006-05-10 KR KR1020077029916A patent/KR101283802B1/ko not_active Expired - Fee Related
- 2006-05-10 US US11/915,110 patent/US20110054153A1/en not_active Abandoned
- 2006-05-10 BR BRPI0611368-0A patent/BRPI0611368A2/pt not_active Application Discontinuation
- 2006-05-10 JP JP2008513521A patent/JP2008542269A/ja active Pending
- 2006-05-10 RU RU2007148007/04A patent/RU2435781C2/ru active
- 2006-05-10 CA CA2609188A patent/CA2609188C/en active Active
- 2006-05-10 EP EP06759514A patent/EP1888624B1/de active Active
- 2006-05-10 ZA ZA200710325A patent/ZA200710325B/xx unknown
- 2006-05-10 MX MX2007014728A patent/MX2007014728A/es active IP Right Grant
- 2006-05-10 AT AT06759514T patent/ATE513850T1/de active
- 2006-05-10 AU AU2006249494A patent/AU2006249494B2/en not_active Ceased
-
2007
- 2007-11-15 IL IL187396A patent/IL187396A/en active IP Right Grant
-
2013
- 2013-01-04 JP JP2013000145A patent/JP2013060471A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007148007A (ru) | 2009-06-27 |
| AU2006249494A1 (en) | 2006-11-30 |
| IL187396A (en) | 2012-08-30 |
| US20110054153A1 (en) | 2011-03-03 |
| RU2435781C2 (ru) | 2011-12-10 |
| WO2006127284A2 (en) | 2006-11-30 |
| HK1113382A1 (en) | 2008-10-03 |
| BRPI0611368A2 (pt) | 2010-08-31 |
| EP1888624B1 (de) | 2011-06-22 |
| US7741285B2 (en) | 2010-06-22 |
| NZ563518A (en) | 2009-12-24 |
| JP2008542269A (ja) | 2008-11-27 |
| ZA200710325B (en) | 2009-08-26 |
| CA2609188A1 (en) | 2006-11-30 |
| AU2006249494B2 (en) | 2011-09-15 |
| EP1888624A2 (de) | 2008-02-20 |
| JP2013060471A (ja) | 2013-04-04 |
| KR101283802B1 (ko) | 2013-07-08 |
| WO2006127284A3 (en) | 2007-03-15 |
| CA2609188C (en) | 2014-05-27 |
| ES2368445T3 (es) | 2011-11-17 |
| US20060009387A1 (en) | 2006-01-12 |
| IL187396A0 (en) | 2008-02-09 |
| CN101228183B (zh) | 2012-06-06 |
| KR20080040637A (ko) | 2008-05-08 |
| MX2007014728A (es) | 2008-02-15 |
| CN101228183A (zh) | 2008-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1669459A4 (de) | Verfahren zur aufreinigung von bernsteinsäure aus fermentationsflüssigkeit | |
| DE602006002843D1 (de) | Verfahren und System zur Fahrzeugführung unter Berücksichtigung von Erntegut | |
| DE112006003916A5 (de) | Zwischenschaltkreis, Brennstoffzellensystem mit Zwischenschaltkreis sowie Verfahren zur Ansteuerung des Zwischenschaltkreises | |
| DE502004008879D1 (de) | Verfahren zur steuerung von energieströmen | |
| DE602007013671D1 (de) | System zur Verringerung von Kraftwerksemissionen | |
| ATE486844T1 (de) | Verfahren zur herstellung von adipodinitril durch hydrocyanierung von 1,3-butadien | |
| DE602007011843D1 (de) | Verfahren zur Herstellung von Gruppe-III-Nitridkristallen | |
| ATE526017T1 (de) | Abscheidung von polyelektrolyten und reinigung von antikörpern | |
| ATE430480T1 (de) | Verfahren zur herstellung von nährmittelzusammensetzungen | |
| EA200970300A1 (ru) | Способ и устройство для опреснения | |
| ATE542803T1 (de) | Verfahren zur herstellung von dihydrochinazolinen | |
| DE602006015090D1 (de) | Verfahren zur herstellung von gezielt durchlässigen laminaten | |
| ATE486841T1 (de) | Verfahren zur herstellung von pregabalin und salzen daraus | |
| ATE449104T1 (de) | Verfahren zur reinigung von fibrinogen | |
| ATE544341T1 (de) | Verfahren zur verbesserung des nematoden toleranten bzw. -resistenten pflanzenwachstums | |
| ATE495286T1 (de) | Verfahren zur hydrolyse von polyphosphorsäure in polyareneazolfasern | |
| DE602007002539D1 (de) | Prozesssteuerungssystem zur Erzeugung von Funktionsblöcken | |
| DE502004001216D1 (de) | Verfahren zur aufreinigung von blausäure | |
| ATE408616T1 (de) | Verfahren zur aufreinigung von il-18-bindendem protein | |
| DE502005010441D1 (de) | Verfahren zur fertigung angepasster, strömungstechnischer oberflächen | |
| ATE513850T1 (de) | Verfahren zur aufreinigung von apo-2-ligand/trail unter anwendung von kristallisation im kalten | |
| EP1960416A4 (de) | Verfahren zur aufreinigung von chenodesoxycholsäure | |
| ATE394369T1 (de) | Verfahren zur aufreinigung von mesotrion | |
| DE602006001916D1 (de) | System und Verfahren zur Ausgabe von Fahrempfehlungen | |
| ATE406811T1 (de) | Verfahren zur herstellung von brühe- oder würzewürfeln |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1888624 Country of ref document: EP |